Please Wait...

Regulatory Expertise

Led by tenured senior executives with extensive clinical research experience, Bioclinica's global cardiac safety and efficacy regulatory expertise is second to none. Bioclinica's unmatched regulatory leadership is well recognized and backed by ongoing professional relationships with key authorities and panels. We have worked with the ICH and FDA to advance industry standards and guidance in the conduct of TQT studies and have successfully completed the first ever regulatory mandated TQT studies in both Japan and China. Bioclinica has supported the design and specific cardiac monitoring technology for our sponsors on studies requested by regulatory authorities. The data from such studies has met the predefined goals established by both sponsor and regulatory organizations.

Bioclinica's regulatory services include:

  • Protocol consultation and guidance throughout development life cycle
  • Fast-tracked ECG and imaging data regulatory submissions and archiving
  • Audit preparation and support
  • FDA ECG warehouse submission
  • Integrated Cardiac Safety Summary reports in support of the alternative approach to formal TQT study requirements

Industry Associations

Bioclinica continues to accelerate drug development, working in tandem with regulatory bodies and key clinical research associations to establish and maintain core lab industry standards for cardiac safety services.

Our contributions include interaction with the following:

  • Metrics Champion Consortium (MCC)
  • Cardiac Safety Research Consortium (CSRC)
  • International CardioOncology Society (ICOS)
  • ICH-E14 expert advisory panel
  • American Society of Hypertension (ASH)
  • American Telemedicine Association (ATA)
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @virtue_insight: #VIphv We are delighted to announce our new Gold Sponsor @bioclinica for our 16th Pharmacovigilance 2018 https://t.co/h…
bioclinica (5 days ago)
RT @bioclinica: Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas R embra…
bioclinica (5 days ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/iW7Q9DfVgQ
bioclinica (2 weeks ago)
Background & key considerations to help #pharma prepare for new FDA blood pressure draft guidance issued in May. Ac… https://t.co/07dJeeD35E
bioclinica (3 weeks ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/tSx5tm2rgg
bioclinica (4 weeks ago)
DYK @bioclinica offers full-svc global clinical data mgmt svcs customizable to your study & program needs? Our high… https://t.co/dyXDiCtWd8
bioclinica (4 weeks ago)

Latest Blogs:

Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations